| Summary | Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making. | Global preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide. |
|---|
| Services | - Biostatistics & Statistical Programming
- Data Management & eClinical
- Regulatory Affairs
- Medical Writing
- Computational & In-Silico Drug Discovery
- Translational Research
- Target Identification & Validation
- High-Throughput Screening
- Medicinal Chemistry
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Safety Pharmacology
- Genetic Toxicology
- Discovery Research
- In Vivo Efficacy Models
- In Vivo PK / PD Studies
- GLP Toxicology
- Preclinical In Vitro Studies
- Preclinical In Vivo Studies
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Phase I Clinical Trials
- Biomarker Assays
- Phase II Clinical Trials
- Phase III Clinical Trials
- Clinical Operations
- Phase IV / Post-Marketing
- US FDA Regulatory Strategy
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy
- China NMPA Regulatory Strategy
- Clinical Trial Services
| - Medicinal Chemistry
- Computational & In-Silico Drug Discovery
- High-Throughput Screening
- Target Identification & Validation
- Discovery Research
- Protein Engineering
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Safety Pharmacology
- Genetic Toxicology
- Preclinical In Vitro Studies
- Preclinical In Vivo Studies
- In Vivo Efficacy Models
- In Vivo PK / PD Studies
- GLP Toxicology
- Carcinogenicity Studies
- DART (Reproductive & Developmental Toxicology)
- Specialized & Large-Animal Models
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Immunogenicity Assays (ADA / NAb)
- Biomarker Assays
- Flow Cytometry Services
- Pathology & Histology Services
- Analytical Method Development & Validation
- ICH Stability Studies
- Translational Research
- Regulatory Affairs
|
|---|
| Locations | - Global network
- Global presence, 30 countries
- Global presence, Multiple, 30 countries, Global
- Global presence, Multiple, 30+ countries
- Global presence, Multiple, 30 countries, International
- Headquarters, Radnor, Pennsylvania, United States
- Global presence, 30 countries
- Global presence, 30+ countries
| - Boston Center of Excellence, Watertown, Massachusetts, USA
- United Kingdom, Sandwich, Kent, United Kingdom
- Europe, Copenhagen, Denmark, Denmark
- Chengdu, Chengdu, China
- Jiangsu, Jiangsu, China
- Shanghai, Shanghai, China
- Malaysia, Malaysia, Malaysia
- Australia, Australia, Australia
- Copenhagen, Copenhagen, Denmark
- Malaysia, Malaysia
- Jiangsu, Jiangsu, China
- Australia, Australia
|
|---|